These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19122120)

  • 1. Differential gene expression in central nervous system lymphoma.
    Rubenstein JL; Shen A; Batchelor TT; Kadoch C; Treseler P; Shuman MA
    Blood; 2009 Jan; 113(1):266-7; author reply 267-8. PubMed ID: 19122120
    [No Abstract]   [Full Text] [Related]  

  • 2. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma.
    Montesinos-Rongen M; Schäfer E; Siebert R; Deckert M
    Acta Neuropathol; 2012 Dec; 124(6):905-6. PubMed ID: 23138649
    [No Abstract]   [Full Text] [Related]  

  • 3. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.
    Sung CO; Kim SC; Karnan S; Karube K; Shin HJ; Nam DH; Suh YL; Kim SH; Kim JY; Kim SJ; Kim WS; Seto M; Ko YH
    Blood; 2011 Jan; 117(4):1291-300. PubMed ID: 21088137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.
    Brunn A; Nagel I; Montesinos-Rongen M; Klapper W; Vater I; Paulus W; Hans V; Blümcke I; Weis J; Siebert R; Deckert M
    Acta Neuropathol; 2013 Oct; 126(4):603-5. PubMed ID: 24061549
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell.
    Montesinos-Rongen M; Brunn A; Bentink S; Basso K; Lim WK; Klapper W; Schaller C; Reifenberger G; Rubenstein J; Wiestler OD; Spang R; Dalla-Favera R; Siebert R; Deckert M
    Leukemia; 2008 Feb; 22(2):400-5. PubMed ID: 17989719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-grade central nervous system lymphoma: clarity through a hazy lens.
    Hauser SL
    Ann Neurol; 2006 May; 59(5):9A-10A. PubMed ID: 16634011
    [No Abstract]   [Full Text] [Related]  

  • 7. MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma.
    Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
    PLoS One; 2019; 14(1):e0210400. PubMed ID: 30615673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma.
    Nakamura T; Yamashita S; Fukumura K; Nakabayashi J; Tanaka K; Tamura K; Tateishi K; Kinoshita M; Fukushima S; Takami H; Fukuoka K; Yamazaki K; Matsushita Y; Ohno M; Miyakita Y; Shibui S; Kubo A; Shuto T; Kocialkowski S; Yamanaka S; Mukasa A; Sasayama T; Mishima K; Maehara T; Kawahara N; Nagane M; Narita Y; Mano H; Ushijima T; Ichimura K
    Acta Neuropathol; 2017 Feb; 133(2):321-324. PubMed ID: 28058506
    [No Abstract]   [Full Text] [Related]  

  • 9. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.
    Bruno A; Alentorn A; Daniau M; Labussière M; Rahimian A; Tabouret E; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Chrétien F; Eimer S; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K
    Acta Neuropathol; 2015 Sep; 130(3):439-40. PubMed ID: 26195323
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.
    Hilal T; Maguire A; Kosiorek HE; Rimsza LM; Rosenthal AC
    Leuk Lymphoma; 2019 Dec; 60(14):3581-3583. PubMed ID: 31246148
    [No Abstract]   [Full Text] [Related]  

  • 11. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
    Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
    Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    Grommes C
    J Clin Oncol; 2023 Mar; 41(9):1649-1651. PubMed ID: 36669147
    [No Abstract]   [Full Text] [Related]  

  • 13. Primary CNS lymphoma.
    Hochberg FH; Baehring JM; Hochberg EP
    Nat Clin Pract Neurol; 2007 Jan; 3(1):24-35. PubMed ID: 17205072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.
    Hayano A; Takashima Y; Yamanaka R
    Int J Clin Oncol; 2019 Sep; 24(9):1020-1029. PubMed ID: 30993483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perivascular microenvironment in primary central nervous system lymphomas: the role of chemokines and the endothelin B receptor.
    Sugita Y; Terasaki M; Nakashima S; Ohshima K; Morioka M; Abe H
    Brain Tumor Pathol; 2015 Jan; 32(1):41-8. PubMed ID: 25433721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the Network Lymphomas and Lymphomatoid Lesions in the Nervous System].
    Brück W; Brunn A; Klapper W; Kuhlmann T; Metz I; Paulus W; Deckert M;
    Pathologe; 2013 May; 34(3):186-97. PubMed ID: 23471726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma.
    Pellissery S; Richter J; Haake A; Montesinos-Rongen M; Deckert M; Siebert R
    Leuk Lymphoma; 2010 Nov; 51(11):2135-6. PubMed ID: 20858097
    [No Abstract]   [Full Text] [Related]  

  • 18. miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma.
    Takashima Y; Kawaguchi A; Iwadate Y; Hondoh H; Fukai J; Kajiwara K; Hayano A; Yamanaka R
    PLoS One; 2020; 15(2):e0229577. PubMed ID: 32101576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas.
    Nakamura M; Ishida E; Shimada K; Nakase H; Sakaki T; Konishi N
    Oncology; 2006; 70(3):212-21. PubMed ID: 16809940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.
    Takashima Y; Hayano A; Yamanaka R
    Clin Cancer Res; 2020 Jun; 26(11):2754-2766. PubMed ID: 32108030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.